Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:IPHA

Innate Pharma 2/14/2026 Earnings Report

Innate Pharma logo
$1.83 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.90 +0.07 (+3.77%)
As of 05/22/2026 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Innate Pharma EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Innate Pharma Revenue Results

Actual Revenue
$2.41 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innate Pharma Announcement Details

Quarter
Date
2/14/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Innate Pharma Earnings Headlines

Innate Pharma to participate in the Jefferies Global Healthcare Conference
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260518085378/en/innate-pharma-to-participate-in-the-jefferies-global-healthcare-conference/
Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript
May 14, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/innate-pharma-s-a-nasdaqipha-q1-2026-earnings-call-transcript-1762053/
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 25 at 1:00 AM  |  Profits Run (Ad)
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
May 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512637251/en/innate-pharma-reports-first-quarter-2026-business-update-and-financial-results/
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260511170262/en/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-16-2026/
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
May 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260505790924/en/innate-pharma-announces-conference-call-and-webcast-for-q1-2026-business-update/
See More Innate Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innate Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innate Pharma and other key companies, straight to your email.

About Innate Pharma

Innate Pharma (NASDAQ:IPHA) SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca. In addition to monalizumab, Innate Pharma’s pipeline includes multiple early- to late-stage candidates such as IPH5201 (anti-TIM-4) and IPH6101 (anti-IL-1RAP), which aim to broaden therapeutic options across solid tumors and hematological malignancies. These assets reflect Innate Pharma’s commitment to advancing precision immunotherapies through strategic partnerships and rigorous clinical development.

Since its inception, Innate Pharma has established a global footprint, conducting multi-center clinical trials across Europe and North America. The company’s research facilities in Marseille support a multidisciplinary team of scientists, clinicians and regulatory experts focused on biomarker-driven approaches. Through collaborations with major pharmaceutical companies, Innate Pharma leverages complementary expertise to accelerate the translation of its discovery efforts into the clinic.

Led by a management team with deep experience in biotechnology product development, Innate Pharma maintains a strategic focus on unlocking the potential of innate immunity for cancer treatment. The company’s operations benefit from a robust intellectual property portfolio and a track record of forging alliances that enhance its capacity to deliver innovative oncology solutions to patients worldwide.

View Innate Pharma Profile
Earnings Tools